Bluejay Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Bluejay Therapeutics's estimated annual revenue is currently $1.6M per year.
- Bluejay Therapeutics's estimated revenue per employee is $77,500
Employee Data
- Bluejay Therapeutics has 21 Employees.
- Bluejay Therapeutics grew their employee count by 17% last year.
Bluejay Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP, Development | Reveal Email/Phone |
2 | VP, Head Chemistry | Reveal Email/Phone |
Bluejay Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Bluejay Therapeutics?
The mission of Bluejay Therapeutics is to develop innovative cures for infectious diseases with the first target indication of chronic HBV infection. Bluejay has exclusively licensed global rights to advance several HBV programs, including a best-in-class anti-HBsAg monoclonal antibody.
keywords:N/A
N/A
Total Funding
21
Number of Employees
$1.6M
Revenue (est)
17%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.5M | 21 | -16% | $13.6M |
#2 | $3.1M | 21 | -5% | N/A |
#3 | $4M | 21 | 5% | N/A |
#4 | $1.4M | 21 | 0% | $4.7M |
#5 | $1.4M | 21 | -80% | $29.1M |